The MDS Foundation proudly partners with the following organizations
The MDS Foundation proudly partners with the following organizations
Phone within the US
1-(800)-637-0839Outside the US only
1-(609)-298-1035Address
The MDS Foundation
228 Park Ave S
PMB 118983
New York
NY 10003-1502
The MDS Foundation is a global nonprofit 501(c)(3) advocacy organization (EIN 22-3283911), supporting patients, families, and healthcare providers in the fields of MDS and related diseases for over 30 years.
© 2024 MDS Foundation. All rights reserved.
Every gift helps patients, caregivers, and healthcare professionals access life-saving resources, support, and education. Together, we can make a difference. Even a small contribution can create a big impact. Thank you for your generosity.
Latest News
Explore the forefront of MDS research, treatments, and community happenings to stay informed on the ever-evolving landscape of MDS care.
December 16, 2025
MDS Foundation ASH Summaries 2025
A comprehensive set of summaries from the MDS Foundation highlighting notable low- and high-risk MDS studies presented at ASH 2025.
December 4, 2025
67th American Society of Hematology Annual Meeting and Exposition Announcement of Presentations
Multiple organisations will present new clinical, translational, and patient-focused research at the 67th American Society of Hematology (ASH) Annual Meeting. Highlights include advances in targeted and combination therapies for MDS and AML, emerging immunotherapies, expanded data on all-oral treatment regimens, and real-world outcomes studies, alongside new evidence on the impact of patient education and shared decision-making.
.png&w=3840&q=75)
October 12, 2025
For patients unlikely to have a fully matched donor, their team should quickly switch to searching for alternate (mismatched) donors
A large BMT CTN trial (1702) found that patients—including those with myelodysplastic syndromes—did just as well at ~2 years when proceeding to transplant with an alternate (mismatched) donor rather than delaying for a fully matched one. The takeaway: timing matters more than perfection—speak with your care team about the best window for transplant.
September 26, 2025
Voices of MDS Featured in touchHAEMATOLOGY
The MDS Foundation is proud to share that the Voices of MDS campaign has been highlighted in touchHAEMATOLOGY as part of Blood Cancer Awareness Month.
August 18, 2025
Inside Information: Faron to advance bexmarilimab into a registrational Phase 2/3 study in treatment-naïve (frontline) HR-MDS after positive meeting with the FDA
Faron announced plans to advance bexmarilimab into a registrational Phase 2/3 study in treatment-naïve (frontline) HR-MDS after positive meeting with the FDA.
August 17, 2025
Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA
Ascentage Pharma announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).
-800x533.jpg&w=3840&q=75)
August 14, 2025
Share Your Voice, Shape the Future: New Survey Feature Launches on the MDS Exchange
The MDS Foundation is excited to announce the launch of a new survey feature within the MDS Exchange, empowering community members to share their specific experiences in a safe, supportive space, while helping shape future care, resources, and research in myelodysplastic syndromes (MDS).
August 5, 2025
Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia
Sent Biosciences announced it has confirmed the recommended Phase 2 dose (RP2D) in its Phase 1 study of SENTI-202, the Company’s potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, in development for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia (AML).
